Investing and Scaling in AI, Precision Medicine and Clinical Trial Access for the Future: VC + Startup Panel
Join us for a dynamic closing session exploring how technology, entrepreneurship, and investment are shaping the future of clinical trial access and precision medicine through the lens of VC investor Julian Eison and Trial Library CSO, Karim Damji.
With a bold vision to expand clinical trial access and transform how evidence is generated in modern healthcare, Trial Library, an AI-enabled research organization and clinical trial platform, is advancing access to cancer precision medicine by helping patients and providers discover relevant clinical trials through intelligent navigation tools. The platform now supports 1,500+ providers and 320+ participating clinics nationwide, and recently raised $10M in a Series A round led by Next Ventures and SemperVirens Venture Capital, reflecting growing momentum around technology-enabled approaches to equitable clinical research.
Together, we will explore how mission-driven innovation becomes a scalable and sustainable solution, examining clinical trial access through both entrepreneurial and venture capital perspectives.
📍 Edwards Building, Room 166
🕒 Thursday, March 12 | 4:30–5:50 PM
About the speaker:
Karim Damji is the Chief Strategy Officer of Trial Library, an AI-enabled platform advancing access to cancer precision medicine and clinical trials. He is a product leader driving development of our AI native enrollment and retention infrastructure.
Julian Eison is the Founding Managing Partner of Penultimate Capital, investing in early-stage companies shaping the future of health, technology, and consumer innovation. Previously Managing Partner at Next Ventures, a $60M+ early-stage fund, he led Seed and Series A investments in companies including Pair Team, Juno Medical, SteadyMD, Trial Library, Vital Biosciences, and Humane, and deployed growth capital into OURA. Julian is also a Lecturer at Stanford Graduate School of Business, where he teaches Startup Garage, and a Kauffman Fellow, committed to supporting entrepreneurs tackling systemic inefficiencies and expanding access to innovation.